Home > Insider Trading > Filing (0001209191-21-063235)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1087294	Cumberland Pharmaceuticals Inc	CPIX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1632384	C Joseph Galante	2525 West End Avenue Suite 950 Nashville TN 37203		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-10-01	142	$2.69	40,937	No	4	P	Direct
Common Stock	Acquisiton	2021-10-04	142	$2.87	41,079	No	4	P	Direct
Common Stock	Acquisiton	2021-10-05	142	$2.82	41,221	No	4	P	Direct
Common Stock	Acquisiton	2021-10-06	142	$2.76	41,363	No	4	P	Direct
Common Stock	Acquisiton	2021-10-07	142	$2.76	41,505	No	4	P	Direct
Common Stock	Acquisiton	2021-10-08	142	$2.84	41,647	No	4	P	Direct
Common Stock	Acquisiton	2021-10-11	142	$2.73	41,789	No	4	P	Direct
Common Stock	Acquisiton	2021-10-12	142	$2.71	41,931	No	4	P	Direct
Common Stock	Acquisiton	2021-10-13	142	$2.71	42,073	No	4	P	Direct
Common Stock	Acquisiton	2021-10-14	142	$2.81	42,215	No	4	P	Direct
Common Stock	Acquisiton	2021-10-15	142	$2.76	42,357	No	4	P	Direct
Common Stock	Acquisiton	2021-10-18	142	$2.75	42,499	No	4	P	Direct
Common Stock	Acquisiton	2021-10-19	142	$2.76	42,641	No	4	P	Direct
Common Stock	Acquisiton	2021-10-20	142	$2.63	42,783	No	4	P	Direct
Common Stock	Acquisiton	2021-10-21	142	$2.65	42,925	No	4	P	Direct
Common Stock	Acquisiton	2021-10-22	142	$2.66	43,067	No	4	P	Direct
Common Stock	Acquisiton	2021-10-25	142	$2.64	43,209	No	4	P	Direct
Common Stock	Acquisiton	2021-10-26	142	$2.64	43,351	No	4	P	Direct
Common Stock	Acquisiton	2021-10-27	142	$2.61	43,493	No	4	P	Direct
Common Stock	Acquisiton	2021-10-28	142	$2.61	43,635	No	4	P	Direct
Common Stock	Acquisiton	2021-10-29	142	$2.72	43,777	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021.